Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027.